Milestone Pharmaceuticals Inc.
MIST evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MIST—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MIST
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing etripamil, an investigational nasal spray for the treatment of cardiovascular conditions such as atrial fibrillation with rapid ventricular rate (AFib-RVR) and paroxysmal supraventricular tachycardia (PSVT).
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$144.4M
Cash Runway
22.9 moLead Asset
cardamyst (Phase 3)
Next Catalyst
Phase3_Topline · Jan 1, 2030Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials · 2 catalysts for Milestone Pharmaceuticals Inc..
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing etripamil, an investigational nasal spray for the treatment of cardiovascular conditions such as atrial fibrillation with rapid ventricular rate (AFib-RVR) and paroxysmal supraventricular tachycardia (PSVT).
- As of June 30, 2026, Milestone had cash and equivalents of $169.7M, total revenue of $0.6M, and a net loss of $28.6M for the quarter [sec].
- The company's lead product candidate is etripamil, a nasal spray being developed for AFib-RVR and PSVT [sec_mda · as of 2026-08-12].
- Milestone has an accumulated deficit of $485.3M as of June 30, 2026, reflecting significant historical operating losses [sec_mda · as of 2026-08-12].
- The company has a Phase 3 topline readout for etripamil in AFib-RVR scheduled for 2030-01-01 [catalyst].
- CARDAMYST, a related product, has a patent/ exclusivity expiry date of 2042-07-15 [catalyst].
What works
- Milestone has a substantial cash position of $169.7M as of June 30, 2026, which may support ongoing development and commercialization efforts [sec].
- The company has a defined regulatory pathway with a Phase 3 trial for etripamil in AFib-RVR, with a topline readout expected in 2030 [catalyst].
- Milestone has secured a royalty interest agreement providing tiered quarterly payments on U.S. net product sales of etripamil, potentially generating non-dilutive revenue [sec_mda · as of 2025-11-12].
What to weigh
- Milestone has incurred significant operating losses, with a net loss of $54.7M for the first six months of 2026 and an accumulated deficit of $485.3M as of June 30, 2026 [sec_mda · as of 2026-08-12].
- The company expects to continue incurring significant losses for the foreseeable future, with expenses increasing as it advances etripamil development and prepares for commercialization [sec_mda · as of 2026-08-12].
- Milestone has no approved products and relies entirely on the successful development and regulatory approval of etripamil, which is inherently uncertain [sec_mda · as of 2026-05-13].
- The company's total debt of $59.2M as of June 30, 2026, adds financial leverage and interest obligations [sec].
From the filings
Quoted directly from source documents.
Milestone has a significant accumulated deficit and expects continued losses.
“As of June 30, 2026, we had an accumulated deficit of $485.3 million. We expect to continue to incur significant losses for the foreseeable future.”
SEC MD&A · August 12, 2026
Milestone has a royalty interest agreement on U.S. net product sales of etripamil.
“to certain conditions), in exchange for a purchase price of $75.0 million, the right to receive a tiered quarterly royalty payments, or "royalty interest," on the annual net product sales of etripamil in the United States.”
SEC MD&A · November 12, 2025
Catalyst timeline
- 2030-01-01 · Phase3_Topline · etripamil — Topline results from a Phase 3 study of etripamil nasal spray in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) will be a key value inflection point.
- 2042-07-15 · Patent_Expiry · CARDAMYST — Patent/exclusivity expiry for CARDAMYST, which may affect long-term market exclusivity.
Risks & what to watch (4)›
Key risks
- No approved products — Milestone has no marketed products and depends entirely on etripamil's regulatory approval, which is uncertain [sec_mda · as of 2026-05-13].
- Significant operating losses — Net loss of $54.7M in H1 2026 and accumulated deficit of $485.3M as of June 30, 2026, with expected continued losses [sec_mda · as of 2026-08-12].
- Clinical development risk — Phase 3 trial for etripamil in AFib-RVR may fail to meet endpoints, delaying or preventing approval [sec_mda · as of 2026-05-13].
- Debt obligations — Total debt of $59.2M as of June 30, 2026, adds financial leverage and interest costs [sec].
What to watch
- Phase 3 topline data for etripamil in AFib-RVR expected in 2030 [catalyst].
- Regulatory updates on etripamil for PSVT and AFib-RVR from the FDA [sec_mda · as of 2026-08-12].
- Cash burn rate and potential need for additional financing given ongoing losses [sec_mda · as of 2026-08-12].
- Commercialization progress for CARDAMYST and etripamil, including sales infrastructure buildout [sec_mda · as of 2026-05-13].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Milestone Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Milestone Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
22.9 months
D/E 8.97
Lead: Phase 3
1 candidate
2 upcoming, next in ~1220d
0 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$28.4M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 6,331,001 | $7.5M |
| two sigma investments, lp | 2,317,176 | $2.8M |
| goldman sachs group inc | 2,000,025 | $2.4M |
| marshall wace, llp | 1,944,530 | $2.3M |
| millennium management llc | 1,544,325 | $1.8M |
| simplify asset management inc. | 1,506,405 | $1.8M |
| balyasny asset management l.p. | 851,325 | $1.0M |
| toronto dominion bank | 750,000 | $893K |
| morgan stanley | 724,141 | $862K |
| boxer capital management, llc | 666,666 | $793K |
Showing top 10 of 82 institutional holders of Milestone Pharmaceuticals Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 8.8%
- Days to cover
- 3.3
- Shares short
- 10,325,577
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MIST short interestGovernance
Frequently asked questions
What is the AI investment thesis for Milestone Pharmaceuticals Inc.?
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing etripamil, an investigational nasal spray for the treatment of cardiovascular conditions such as atrial fibrillation with rapid ventricular rate (AFib-RVR) and paroxysmal supraventricular tachycardia (PSVT).
What is Milestone Pharmaceuticals Inc.'s lead drug candidate?
Milestone Pharmaceuticals Inc.'s most advanced tracked candidate is cardamyst (Phase 3) for paroxysmal supraventricular tachycardia (PSVT).
What is Milestone Pharmaceuticals Inc.'s next catalyst?
Milestone Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atria" — expected January 1, 2030.
Who is the CEO of Milestone Pharmaceuticals Inc.?
Mr. Joseph G. Oliveto M.B.A. is the chief executive officer of Milestone Pharmaceuticals Inc. (MIST).
Where is Milestone Pharmaceuticals Inc. headquartered?
Milestone Pharmaceuticals Inc. (MIST) is headquartered in Montreal, QC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.